Stiripentol for the treatment of seizures associated with Dravet syndrome

References

• Chiron C. Stiripentol. Neurotherapeutics. 2007;4(1):123–125.
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119–140.
   PubMed Web of Science ®Google Scholar
• Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl2):76–78.
   PubMedGoogle Scholar
• Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol. 2012;16(Suppl 1):S13–S17.
   PubMedGoogle Scholar
• Plosker GL. Stiripentol: in severe myoclonic epilepsy of infancy (dravet syndrome). CNS Drugs. 2012;26(11):993–1001.
   PubMed Web of Science ®Google Scholar
• Brigo F, Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database Syst Rev. 2013;19(11):CD010483.
   Google Scholar
• Verrotti A, Prezioso G, Stagi S, et al. Pharmacological considerations in the use of stiripentol for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2016;12(3):345–352.
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(8):1091–1101.
   PubMed Web of Science ®Google Scholar
• Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017;31(5):405–416.
   PubMed Web of Science ®Google Scholar
• Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136:e1310–e1315.
   PubMed Web of Science ®Google Scholar
• Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627–633.
   PubMedGoogle Scholar
• Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508–512.
   PubMed Web of Science ®Google Scholar
• Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr. 2002;9:1120–1127.
   PubMed Web of Science ®Google Scholar
• de Lange IM, Gunning B, Sonsma ACM, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59(6):1154-1165..
   Google Scholar
• Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):S72–S75.
   PubMedGoogle Scholar
• Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32(Apr):335–350. Erratum in: CNS Drugs. 2018;32:783.
   PubMedGoogle Scholar
• Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-receptor channels. Epilepsia. 2006;47:704–716.
   PubMed Web of Science ®Google Scholar
• Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190–197.
   PubMed Web of Science ®Google Scholar
• Auvin S, Lecointe C, Dupuis N, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013;54(12):2082–2090.
   PubMed Web of Science ®Google Scholar
• Grosenbaugh DK, Mott DD. Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology. 2013;67:136–143.
   PubMed Web of Science ®Google Scholar
• Cao D, Ohtani H, Ogiwara I, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome. Epilepsia. 2012;53(7):1140–1145.
   PubMed Web of Science ®Google Scholar
• Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410.
   PubMed Web of Science ®Google Scholar
• Sada N, Lee S, Katsu T, et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362–1367. Epilepsy treatment.
   PubMed Web of Science ®Google Scholar
• Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94:179–189.
   PubMed Web of Science ®Google Scholar
• Patsalos P, Zugman M, Lake C, et al. Serum protein binding of 25 antepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58:1234–1243.
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356(9242):1638–1642.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Tonnelier S, d’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43(Suppl 8):S155.
   Google Scholar
• May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390–397.
   PubMed Web of Science ®Google Scholar
• Peigné S, Rey E, Le Guern ME, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108(5):909–916.
   PubMed Web of Science ®Google Scholar
• Peigné S, Chhun S, Tod M, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57(6):739–748.
   PubMed Web of Science ®Google Scholar
• Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59:1705–1717.
   PubMed Web of Science ®Google Scholar
• Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490–504.
   PubMed Web of Science ®Google Scholar
• Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608–611.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, STP-1 Study Group. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014 May; 108(4):725–731.
   PubMed Web of Science ®Google Scholar
• Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–1626.
   PubMed Web of Science ®Google Scholar
• Jullien V, Chhun S, Rey E, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid. Clin Pharmacokinet. 2015;54:527–536.
   PubMed Web of Science ®Google Scholar
• Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017;130:7–12.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Effect of CYP inducers/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39:55–61.
   PubMed Web of Science ®Google Scholar
• Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37:325–329.
   PubMed Web of Science ®Google Scholar
• de Liso P, Chemaly N, Laschet J, et al. Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;51:42–46.
   Google Scholar
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86–95.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–e1211.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized,open-label, single-dose, 3 period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57:11–19.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Auvin S, Zuberi S, et al. Fenfluramine (fintepla®) reduces convulsive seizure frequency in Dravet syndrome patients receiving an antiepileptic drug treatment regimen containing stiripentol: a Phase 3, randomized, placebo-controlled clinical trial. New Orleans (LA): American Epilepsy Society; 2018.
   Google Scholar
• Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49:343–348.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50:2362–2368.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y; STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–97.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54(9):1595–1604.
   PubMed Web of Science ®Google Scholar
• Pembegul Yıldız E, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2018;26:883073818811538.
   Google Scholar
• Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12 year observational study. Dev Med Child Neurol. 2018;60:574–578.
   PubMed Web of Science ®Google Scholar
• Takayama R, Fujiwara T, Shigematsu H, et al. Long-term course of Dravet syndrome: a study from an epilepsy center in Japan. Epilepsia. 2014;55(4):528–538.
   PubMed Web of Science ®Google Scholar
• Diacomit: EPAR - product information 2013. [cited 2019 Mar 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000664/WC500036518.pdf
   Google Scholar
• Akiyama M, Kobayashi K, Yoshinaga H, et al. A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia. 2010;51(6):1043–1052.
   PubMed Web of Science ®Google Scholar
• Catarino CB, Liu JY, Liagkouras I, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain. 2011;134:2982–3010.
   PubMed Web of Science ®Google Scholar
• Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135:73–79.
   PubMed Web of Science ®Google Scholar
• Biocodex. BC.627 - DIAVEY - DIACOMIT Post-Marketing Survey (Stiripentol). Post-authorization safety study, final study report. 14 December 2012.
   Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86–91.
   PubMed Web of Science ®Google Scholar
• Rosander C, Hallböök T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol. 2015 Mar 13; DOI:10.1111/dmcn.12709
   PubMed Web of Science ®Google Scholar
• Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–89.
   PubMed Web of Science ®Google Scholar
• Kouga T, Shimbo H, Iai M, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37(2):243–249.
   PubMed Web of Science ®Google Scholar
• Cetica V, Chiari S, Mei D, et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology. 2017;88:1037–1044.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54–e57.
   PubMed Web of Science ®Google Scholar
• Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–109.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kortland LM, Knake S, et al. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132(6):435–439.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Terada K, Madokoro Y, et al. Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity. Acta Neurol Scand. 2018;137:432–437.
   PubMed Web of Science ®Google Scholar
• Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017;44:58–64.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans AS, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–e134. Erratum in: Epilepsia 2017;58:509–10.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Cross JH, et al. ZX008 (fenfluramine HCI oral solution) in Dravet syndrome: results of a Phase 3, randomized, double-blind, placebo-controlled trial. Washington (DC): American Epilepsy Society; 2017.
   Google Scholar
• Brigo F, Striano P, Balagura G, et al. Emerging drugs for the treatment of Dravet syndrome. Expert Opin Emerg Drugs. 2018 Nov 27; DOI:10.1080/14728214.2018.1552937
   PubMedGoogle Scholar